What is the appropriate initial management for a patient in the early phase of infectious mononucleosis with mildly elevated liver enzymes?

Management of Elevated LFTs in Early Infectious Mononucleosis

For a patient with early infectious mononucleosis and mildly elevated liver enzymes, no specific treatment is required—management is supportive only, with serial monitoring of liver function tests unnecessary in immunocompetent patients.

Initial Approach

The presence of elevated liver enzymes in infectious mononucleosis is expected and typically benign. Approximately 80-90% of patients with infectious mononucleosis develop abnormal liver function tests during the acute phase 1, 2. This hepatic involvement is subclinical in most cases and resolves spontaneously without intervention.

Key Management Principles

Supportive care is the cornerstone of treatment:

• Adequate hydration and rest as tolerated (not enforced bed rest)
• Analgesics and antipyretics for symptom control
• Activity level should be guided by the patient's energy 3

No routine serial liver function monitoring is needed in immunocompetent adults with subclinical liver enzyme elevation 1. A retrospective study of 153 patients demonstrated that liver function tests typically normalize within a median of 32 days (range 20-50 days, maximum 10 months), and no patients developed liver disease sequelae despite the lack of routine follow-up monitoring 1.

What NOT to Do

Avoid routine use of:

• Corticosteroids (not indicated for uncomplicated hepatic involvement) 4, 3
• Antiviral agents like acyclovir (not recommended for routine treatment) 4, 3
• Abdominal ultrasound (not necessary unless clinical concern for other pathology) 1

When to Escalate Care

Immediate intervention is required only if the patient develops:

• Signs of liver failure: jaundice, coagulopathy (prolonged PT), hepatic encephalopathy, or ascites
• Severe pharyngeal edema or respiratory compromise (corticosteroids may be indicated in these specific scenarios) 3
• Evidence of splenic rupture (abdominal pain, hemodynamic instability)

Activity Restrictions

Patients must avoid contact or collision sports for at least 3-4 weeks from symptom onset to prevent splenic rupture, which occurs in 0.1-0.5% of cases and is the most feared complication 5, 4, 3. This restriction should be maintained for 8 weeks or while splenomegaly persists 5.

Follow-Up Considerations

Routine follow-up liver function testing is not indicated unless:

• The patient is immunosuppressed (higher risk of severe disease) 4
• Clinical symptoms suggest progressive liver dysfunction
• Initial presentation includes signs of hepatic compromise

The evidence clearly demonstrates that in immunocompetent patients with subclinical liver enzyme elevation, serial assessment adds no clinical value and liver function normalizes spontaneously 1.

Common Pitfalls to Avoid

1. Over-investigation: Do not order serial liver function tests or imaging in uncomplicated cases—this increases cost without improving outcomes
2. Premature return to sports: Ensure the 3-4 week minimum restriction is maintained regardless of how well the patient feels
3. Inappropriate corticosteroid use: Reserve for life-threatening complications only (airway obstruction, severe hemolytic anemia, thrombocytopenia), not for routine hepatic involvement
4. Misinterpreting heterophile antibody tests: These can be falsely negative in the first week of illness and in children under 5 years 4—if clinical suspicion is high with negative heterophile test, the presence of elevated liver enzymes actually increases the likelihood of infectious mononucleosis and may warrant EBV-specific antibody testing